Cogent Biosciences, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020, compared with FY2019. Cogent is a clinical-stage biotechnology company developing precision therapies. Its lead candidate, CGT9486, is being developed for systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). The company reported no product sales.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Collaboration revenue | $7.9 million | $22.5 million |
| Research and development expense | $25.7 million | $43.7 million |
| General and administrative expense | $17.4 million | $11.0 million |
| Acquired in-process R&D expense | $46.9 million | — |
| Loss from operations | $82.2 million | $32.2 million |
| Net loss | $74.8 million | $31.8 million |
| Net loss attributable to common shareholders | $179.2 million | $31.8 million |
| Basic and diluted loss per share | $16.17 | $4.18 |
| Cash used in operating activities | $35.9 million | $41.5 million |
| Cash and cash equivalents at year-end | $242.2 million | $37.4 million |
| Total assets | $250.9 million | $49.4 million |
| Total liabilities | $16.2 million | $17.7 million |
Gross margin is not meaningful for this development-stage company and is not presented. No borrowings are reported; liabilities included $5.2 million of operating lease obligations and a $5.5 million contingent value right (CVR) liability. Current assets were $244.9 million and current liabilities were $13.1 million at year-end.
Material changes versus FY2019
- Net loss increased to $74.8 million from $31.8 million, reflecting $46.9 million of acquired in-process R&D expense for the Kiq asset acquisition, lower collaboration revenue, and higher G&A expense. The acquired expense was noncash consideration in substantial part.
- Revenue fell as the Seagen collaboration ended in January 2020; all related performance obligations were completed and no deferred revenue remained at year-end.
- R&D expense declined, mainly following the wind-down of legacy cell-therapy programs and a workforce reduction of approximately 60% (43 employees). G&A expense rose with personnel and transaction-related costs.
- Cash rose materially following equity financing: net proceeds of $98.9 million from a July PIPE and approximately $107.7 million from a December common-stock offering, plus $25.0 million raised through the Lincoln Park facility. Financing cash flow was $232.2 million.
- Operating cash use was $35.9 million; investing activities provided $8.4 million, largely from the BOXR asset sale. The company recorded a $7.5 million gain on disposal of long-lived assets.
- Common shares outstanding increased substantially during the year. The filing also reports 132,244 Series A preferred shares outstanding at year-end, convertible subject to specified ownership limits.
Outlook, commentary, and risks
- Management estimated year-end cash would fund operating and capital expenditure needs into 2024. This is a forecast based on assumptions; the filing cautions that spending or development outcomes could cause cash to be exhausted sooner. Additional financing may be needed.
- Subject to regulatory feedback, Cogent planned to start an AdvSM trial in the first half of 2021, a Non-AdvSM trial in the second half, and an imatinib-resistant GIST study in the second half. The company also planned FDA discussions on CGT9486 plus sunitinib in GIST.
- In a small Phase 1/2 GIST combination-trial subset of 15 patients without prior CGT9486 monotherapy, the reported confirmed objective response rate was 20% (two partial and one complete response) and estimated median progression-free survival was 12 months. The limited sample size and trial design constrain interpretation.
- CGT9486 and any future candidates remain subject to clinical, regulatory, manufacturing, and commercialization risks. The FDA may require additional or later-stage trials; early results may not predict subsequent outcomes.
- CGT9486 supply relied on single-source third-party suppliers, with no long-term supply arrangements disclosed. COVID-19 could disrupt trials, vendors, manufacturing, or financing; the company reported no material COVID-19 impact as of December 31, 2020.
- The Plexxikon license carries up to $7.5 million in clinical milestones, up to $25.0 million in regulatory milestones, and tiered low- to high-single-digit royalties on sales. Potential BOXR sale milestones of up to $3.4 million were not recognized at year-end.
- Ownership changes restricted use of tax attributes; the company wrote off certain previously reserved NOLs and credits. A full valuation allowance remained against deferred tax assets.
- PricewaterhouseCoopers issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; no auditor attestation of internal controls was included under the emerging-growth-company exemption.
Investor facts to verify
- Whether planned 2021 CGT9486 trials began on schedule and what regulatory feedback required.
- How later, larger and controlled studies compare with the preliminary GIST response and progression-free-survival data.
- Cash burn, trial costs, and whether management’s “into 2024” cash-runway estimate remains supportable.
- Potential dilution from preferred-stock conversions, outstanding options, CVR settlements, or future capital raises.
- Progress in establishing backup CGT9486 suppliers and the status of any remaining BOXR milestone payments.
- The effect of Section 382 limitations on the company’s ability to use remaining tax attributes.